Systemic therapy or radiotherapy within 4 weeks prior to Day 1 
Prior therapy with agents targeting the DR5 apoptosis pathway 
Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to Day 1, or anticipation of need for major surgical procedure during the course of the study 
Other invasive malignancies within 5 years prior to Day 1 
Known active brain metastases 
Uncontrolled intercurrent illness, including but not limited to ongoing or active infection requiring parenteral antibiotics at enrollment 
Clinically significant, symptomatic cardiovascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia, Grade II or greater peripheral vascular disease, or history of major heart surgery within 6 months of Day 1, or any situation that would likely limit compliance with study requirements 
Known to be positive for hepatitis C or hepatitis B surface antigen 
History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications 
Use of anticoagulation therapy 
Participation in clinical trials or undergoing other investigational procedures within 30 days prior to Day 1 
Pregnancy or breast feeding 
Known sensitivity to any of the products administered during the study 
Any disorder that compromises the ability of the patient to give written informed consent and/or comply with study procedures       
    

NCT00543712_exc_T1
Procedure
Systemic therapy
NCT00543712_exc_T2
Procedure
radiotherapy
NCT00543712_exc_T3
Temporal
within 4 weeks prior to Day 1
NCT00543712_exc_T4
Reference_point
Day 1
NCT00543712_exc_T5
Scope
Systemic therapy or radiotherapy
NCT00543712_exc_T6
Temporal
Prior
NCT00543712_exc_T7
Procedure
therapy
NCT00543712_exc_T8
Drug
agents targeting the DR5 apoptosis pathway
NCT00543712_exc_T9
Qualifier
Major
NCT00543712_exc_T10
Procedure
surgical procedure
NCT00543712_exc_T11
Procedure
open biopsy
NCT00543712_exc_T12
Qualifier
significant
NCT00543712_exc_T13
Condition
traumatic injury
NCT00543712_exc_T14
Temporal
within 4 weeks prior to Day 1
NCT00543712_exc_T15
Reference_point
Day 1
NCT00543712_exc_T16
Scope
Major surgical procedure, open biopsy, or significant traumatic injury
NCT00543712_exc_T17
Mood
anticipation of need
NCT00543712_exc_T18
Qualifier
major
NCT00543712_exc_T19
Procedure
surgical procedure
NCT00543712_exc_T20
Temporal
during the course of the study
NCT00543712_exc_T21
Reference_point
the study
NCT00543712_exc_T22
Qualifier
Other
NCT00543712_exc_T23
Condition
invasive malignancies
NCT00543712_exc_T24
Temporal
within 5 years prior to Day 1
NCT00543712_exc_T25
Reference_point
Day 1
NCT00543712_exc_T26
Qualifier
active
NCT00543712_exc_T27
Condition
brain metastases
NCT00543712_exc_T28
Temporal
active
NCT00543712_exc_T29
Qualifier
Uncontrolled
NCT00543712_exc_T30
Condition
intercurrent illness
NCT00543712_exc_T31
Temporal
ongoing
NCT00543712_exc_T32
Qualifier
active
NCT00543712_exc_T33
Condition
infection
NCT00543712_exc_T34
Drug
parenteral antibiotics
NCT00543712_exc_T35
Temporal
at enrollment
NCT00543712_exc_T36
Scope
ongoing or active
NCT00543712_exc_T37
Scope
Uncontrolled intercurrent illness
NCT00543712_exc_T38
Scope
ongoing or active infection requiring parenteral antibiotics at enrollment
NCT00543712_exc_T39
Reference_point
enrollment
NCT00543712_exc_T40
Qualifier
Clinically significant
NCT00543712_exc_T41
Qualifier
symptomatic
NCT00543712_exc_T42
Condition
cardiovascular disease
NCT00543712_exc_T43
Measurement
New York Heart Association (NYHA)
NCT00543712_exc_T44
Value
Grade II or greater
NCT00543712_exc_T45
Condition
congestive heart failure
NCT00543712_exc_T46
Qualifier
serious
NCT00543712_exc_T47
Condition
cardiac arrhythmia
NCT00543712_exc_T48
Value
Grade II or greater
NCT00543712_exc_T49
Condition
peripheral vascular disease
NCT00543712_exc_T50
Observation
history of
NCT00543712_exc_T51
Qualifier
major
NCT00543712_exc_T52
Procedure
heart surgery
NCT00543712_exc_T53
Temporal
within 6 months of Day 1
NCT00543712_exc_T54
Reference_point
Day 1
NCT00543712_exc_T55
Scope
peripheral vascular disease, or history of major heart surgery limit compliance
NCT00543712_exc_T56
Observation
limit compliance
NCT00543712_exc_T57
Value
positive
NCT00543712_exc_T58
Measurement
hepatitis C
NCT00543712_exc_T59
Measurement
hepatitis B surface antigen
NCT00543712_exc_T60
Scope
hepatitis C or hepatitis B surface antigen
NCT00543712_exc_T61
Observation
History
NCT00543712_exc_T62
Qualifier
other
NCT00543712_exc_T63
Condition
disease
NCT00543712_exc_T64
Condition
metabolic dysfunction
NCT00543712_exc_T65
Procedure
physical examination
NCT00543712_exc_T66
Condition
physical examination finding
NCT00543712_exc_T67
Condition
clinical laboratory finding
NCT00543712_exc_T68
Procedure
clinical laboratory
NCT00543712_exc_T69
Mood
suspicion of
NCT00543712_exc_T70
Condition
disease
NCT00543712_exc_T71
Condition
condition
NCT00543712_exc_T72
Condition
contraindicates
NCT00543712_exc_T73
Scope
disease or condition
NCT00543712_exc_T74
Scope
suspicion of a disease or condition
NCT00543712_exc_T75
Drug
investigational drug
NCT00543712_exc_T76
Observation
affect interpretation of the results
NCT00543712_exc_T77
Observation
render the patient at high risk
NCT00543712_exc_T78
Condition
treatment complications
NCT00543712_exc_T79
Scope
contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications
NCT00543712_exc_T80
Procedure
anticoagulation therapy
NCT00543712_exc_T81
Drug
anticoagulation
NCT00543712_exc_T82
Observation
Participation in clinical trials
NCT00543712_exc_T83
Observation
undergoing other investigational procedures
NCT00543712_exc_T84
Temporal
within 30 days prior to Day 1
NCT00543712_exc_T85
Reference_point
prior to Day 1
NCT00543712_exc_T86
Scope
Participation in clinical trials or undergoing other investigational procedures
NCT00543712_exc_T87
Condition
Pregnancy
NCT00543712_exc_T88
Observation
breast feeding
NCT00543712_exc_T89
Condition
sensitivity
NCT00543712_exc_T90
Drug
any of the products administered during the study
NCT00543712_exc_T91
Condition
disorder
NCT00543712_exc_T92
Negation
compromises the ability of
NCT00543712_exc_T93
Measurement
give written informed consent
NCT00543712_exc_T94
Procedure
comply with study procedures
NCT00543712_exc_T95
Scope
give written informed consent and/or comply with study procedures